Diagnostic Approach to Diabetes Mellitus

Overview

• Goodman & Gilman's Pharmacological Basis of Therapeutics
• Harrison's Principles of Internal Medicine, 22nd Ed.
• Tietz Textbook of Laboratory Medicine, 7th Ed.
• Robbins & Kumar Basic Pathology
• Guyton and Hall Textbook of Medical Physiology

Step 1: Recognize Clinical Features

Step 2: Diagnostic Tests

1. Fasting Plasma Glucose (FPG)

• Fast for at least 8 hours (no caloric intake)
• Normal: <100 mg/dL (<5.6 mmol/L)
• Prediabetes (IFG): 100-125 mg/dL (5.6-6.9 mmol/L)
• Diabetes: ≥126 mg/dL (≥7.0 mmol/L)
• Limitation: Large biological variation (day-to-day), lower sensitivity than OGTT, risk of glycolysis in the test tube if processing is delayed.

2. Oral Glucose Tolerance Test (OGTT)

• 75 g anhydrous glucose dissolved in 300 mL water, ingested over 5 minutes
• Plasma glucose measured at fasting and at 2 hours
• For children: 1.75 g/kg body weight (up to 75 g maximum)
• Normal: 2h PG <140 mg/dL
• Prediabetes (IGT): 2h PG 140-199 mg/dL
• Diabetes: 2h PG ≥200 mg/dL (≥11.1 mmol/L)

• Unrestricted diet with ≥150 g carbohydrate/day for 3 days prior
• 10-16 hour overnight fast
• Ambulatory outpatient (not hospitalized or acutely ill)
• Avoid medications affecting glucose tolerance (thiazides, corticosteroids, oral contraceptives)
• No smoking or caffeine during the test
• Remain seated; test begins between 7:00-9:00 AM

• Diagnosis of gestational diabetes mellitus (GDM)
• Initial postpartum screening for T2DM in women with GDM
• Diagnosing impaired glucose tolerance (IGT)
• Evaluation of unexplained nephropathy/neuropathy/retinopathy with random glucose <140 mg/dL

3. HbA1c (Glycated Hemoglobin)

• Reflects average blood glucose over the previous 2-3 months (based on the ~120-day RBC lifespan)
• Prediabetes: 5.7-6.4%
• Diabetes: ≥6.5% (≥48 mmol/mol)
• Advantages over glucose testing: No fasting required, low biological variability, sample is stable, reflects long-term control
• Requirements: Must be performed in a laboratory using an NGSP-certified method standardized to the DCCT assay. Point-of-care assays should generally not be used for diagnosis (though some POC assays now meet NGSP criteria per Harrison's 2024 update).
• Limitations/Contraindications: Unreliable in hemolytic anemias, hemoglobinopathies (sickle cell, thalassemia), iron deficiency anemia, recent blood transfusion, pregnancy, or chronic kidney disease.

4. Random Plasma Glucose

• Taken at any time, regardless of last meal
• Diabetes: ≥200 mg/dL (≥11.1 mmol/L) with classic symptoms of hyperglycemia (polyuria, polydipsia, unexplained weight loss) or hyperglycemic crisis
• This criterion alone is diagnostic only when classic symptoms are present

Step 3: Confirmation Rule

Important: Stress hyperglycemia from severe infections, burns, or trauma (due to catecholamines/cortisol) can cause transient hyperglycemia. Diabetes requires persistent hyperglycemia after resolution of the acute illness.

Step 4: Interpret the Spectrum - Normal, Prediabetes, Diabetes

• Prediabetes confers 5-10% annual risk of progressing to T2DM; risk is highest with obesity and family history
• Individuals with both IFG and IGT have a higher conversion rate than either alone
• Prediabetes also carries elevated cardiovascular disease risk independent of overt diabetes

Step 5: Classify the Type of Diabetes

• Plasma insulin/C-peptide: Very low or undetectable in T1; normal or elevated in early T2
• Autoantibodies (GAD65, IA-2, ZnT8, IAA): Positive in ~95% of T1DM
• After glucose load: T2DM shows exaggerated insulin secretion relative to basal; T1DM shows flat or no response

Step 6: Additional Tests in Specific Contexts

Screening (Who to Test Without Symptoms?)

• Adults ≥35 years of age (regardless of BMI)
• Overweight/obese adults (BMI ≥25, or ≥23 in Asian Americans) with one or more risk factors:
  • First-degree relative with diabetes
  • High-risk ethnicity (African American, Latino, Native American, Asian American, Pacific Islander)
  • History of GDM or delivering a baby >9 lbs
  • Hypertension (≥140/90 or on antihypertensive therapy)
  • Dyslipidemia (HDL <35 mg/dL or TG >250 mg/dL)
  • Polycystic ovary syndrome (PCOS)
  • Physical inactivity
  • Previous prediabetes
  • HIV infection

Summary Algorithm

Clinical suspicion or screening trigger
        |
        v
Choose test:  FPG (fasting ≥8h)  |  OGTT (75g, 2h PG)  |  HbA1c  |  Random PG
        |
        v
Classic symptoms + random PG ≥200?  -->  Diagnose DM (single test sufficient)
        |
        No classic symptoms?
        v
Result meets DM threshold?
  Yes --> Repeat on separate occasion (OR use second test from same sample)
  Both abnormal --> Diagnose DM
        |
        v
Result in prediabetes range?  -->  Lifestyle intervention, rescreen q1 year
        |
        v
Normal?  -->  Rescreen every 3 years (or annually if high risk)
        |
        v
Classify type (T1, T2, GDM, MODY, secondary) based on clinical features + C-peptide + autoantibodies

• Tietz Textbook of Laboratory Medicine, 7th Ed. - Box 47.3 (Criteria for Diagnosis), p. 1731-1732
• Robbins & Kumar Basic Pathology - Diagnosis section, p. 2425-2435
• Guyton and Hall Medical Physiology - Physiology of Diagnosis, p. 976-977
• Harrison's Principles of Internal Medicine, 22nd Ed. - Standards of Care 2024 update
• Goodman & Gilman's Pharmacological Basis of Therapeutics - Pathophysiology and Diagnosis, p. 2271-2276
• Tintinalli's Emergency Medicine - Diagnosis, p. 2555-2558